The European Commission (EC) and the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) granted Mylan the right to market TOBI Podhaler (tobramycin inhalation powder) and TOBI Solution (tobramycin nebulizer solution) in the United Kingdom, the company announced.
Tobramycin is an inhaled antibiotic used to treat chronic lung infections caused by Pseudomonas aeruginosa in adults and children, ages six or older, with cystic fibrosis (CF). Repeat bacterial infections damage the lungs, leading to scarring (fibrosis) and raising a risk of respiratory failure.
The medicine is currently commercialized as a nebulizer solution, sold under the brand name TOBI Solution (300 mg/5 ml for nebulisation), or as dry powder capsules and sold under the brand name TOBI Podhaler (28 mg per capsule). Both medications require the use of a specialized inhaler to be administered properly.
Mylan welcomed the decision by European regulatory authorities, saying it represents the company’s continuing commitment to CF patients and life quality. About 10,500 people in the U.K. are living with CF, a medical condition that requires rigorous treatment and follow-up.
“We’re very pleased that Mylan becomes the marketing authorisation holder for TOBI Podhaler and TOBI Solution,” Jose Cotarelo, Mylan area director for Northern Europe, said in a press release. “Mylan have continually supported the cystic fibrosis community and as treatments improve, patients are living longer. It is imperative therefore, that we continue to develop care regimes that improve patients’ quality of life.”